Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $694000.0.

  • Regenxbio's Change in Account Payables fell 7778.49% to $694000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 22393.36%. This contributed to the annual value of -$292000.0 for FY2024, which is 8953.78% up from last year.
  • As of Q3 2025, Regenxbio's Change in Account Payables stood at $694000.0, which was down 7778.49% from $2.5 million recorded in Q2 2025.
  • Regenxbio's Change in Account Payables' 5-year high stood at $16.8 million during Q1 2022, with a 5-year trough of -$14.9 million in Q2 2024.
  • Moreover, its 5-year median value for Change in Account Payables was $1.2 million (2023), whereas its average is $683157.9.
  • Within the past 5 years, the most significant YoY rise in Regenxbio's Change in Account Payables was 592697.84% (2022), while the steepest drop was 54248.89% (2022).
  • Quarter analysis of 5 years shows Regenxbio's Change in Account Payables stood at -$8.8 million in 2021, then surged by 121.65% to $1.9 million in 2022, then crashed by 36.03% to $1.2 million in 2023, then soared by 149.02% to $3.0 million in 2024, then tumbled by 77.16% to $694000.0 in 2025.
  • Its Change in Account Payables was $694000.0 in Q3 2025, compared to $2.5 million in Q2 2025 and -$3.7 million in Q1 2025.